Alembic Pharmaceuticals Ltd's Q4FY25 Quarter Results
- 07 May 2025
Result Summary
- Alembic Pharmaceuticals Ltd reported a 10.7% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a growth of 8.0%.
- Its expenses for the quarter were down by 12.3% QoQ and up 4.3% YoY.
- The net profit increased 29.4% QoQ and increased 16.8% YoY.
- The earnings per share (EPS) of Alembic Pharmaceuticals Ltd stood at 9.1 during Q4FY25.
Financial Statments for Q4FY25
| (₹ crores) | Q4FY25 | Q3FY25 | Q4FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 1520.58 | 1702.24 | 1407.34 | -10.7% | 8.0% |
Total Expenses | 1337.34 | 1524.82 | 1282.72 | -12.3% | 4.3% |
Profit Before Tax | 183.24 | 177.42 | 124.62 | 3.3% | 47.0% |
Tax | 4.64 | 40.08 | -36.43 | -88.4% | -112.7% |
Profit After Tax | 178.21 | 137.70 | 152.60 | 29.4% | 16.8% |
Earnings Per Share | 9.10 | 7.00 | 7.80 | 30.0% | 16.7% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Alembic Pharmaceuticals Ltd is a prominent player in the pharmaceutical industry, known for manufacturing and marketing pharmaceutical products globally. Its primary business includes the production of both branded and generic formulations, as well as active pharmaceutical ingredients (APIs). The company has a notable presence in various therapeutic segments such as anti-infective, anti-inflammatory, and cardiology. While specific recent developments are not provided here, the company operates in a competitive market characterized by rapid technological advancements and stringent regulatory standards.
Revenue
In the fourth quarter of the fiscal year 2025 (Q4FY25), Alembic Pharmaceuticals Ltd recorded a total income of ₹1520.58 crores. This represents a decrease of 10.7% compared to the previous quarter (Q3FY25), where the total income was ₹1702.24 crores. However, when compared to the same quarter in the previous year (Q4FY24), there was an increase of 8.0%, as the total income then was ₹1407.34 crores. The year-over-year growth indicates a positive trend in the company's revenue generation capability over the past year despite the quarterly decline.
Profitability
The company's profitability in Q4FY25 is highlighted by a Profit Before Tax (PBT) of ₹183.24 crores, which is a 3.3% increase from ₹177.42 crores in Q3FY25 and a significant 47.0% rise from ₹124.62 crores in Q4FY24. The Profit After Tax (PAT) for Q4FY25 stood at ₹178.21 crores, marking a substantial quarter-over-quarter increase of 29.4% from ₹137.70 crores in Q3FY25, and a year-over-year increase of 16.8% from ₹152.60 crores in Q4FY24. The Earnings Per Share (EPS) also rose to ₹9.10, reflecting a 30.0% increase quarter-over-quarter and a 16.7% increase year-over-year, indicating improved profitability performance.
Operating Metrics
Total expenses for Alembic Pharmaceuticals Ltd in Q4FY25 were ₹1337.34 crores, reflecting a decrease of 12.3% from ₹1524.82 crores in Q3FY25, but an increase of 4.3% compared to ₹1282.72 crores in Q4FY24. The effective tax expense for the quarter was ₹4.64 crores, a significant reduction of 88.4% from ₹40.08 crores in the previous quarter. This tax figure also contrasts sharply with the negative tax value of -₹36.43 crores in Q4FY24, indicating a return to positive tax obligations. These metrics, alongside the observed changes in income and profitability, provide a comprehensive view of the company's operational efficiency and financial management during the quarter.
